Chiesi Returns Seralutinib Rights to Gossamer Bio as Companies Terminate Collaboration and License Agreement
27 July 2026
Chiesi Marks Significant Step in its Net Zero Journey with MHRA Approval of its First Pressurized Metered-Dose Inhalers Containing a Next-Generation, Low GWP Propellant
20 July 2026
Chiesi and Oak Hill Bio Holdings complete patient enrollment in the Phase 2b FOOTPRINTS study
03 July 2026
U.S. FDA approves TRIMBOW® - Chiesi’s Single Inhaler Triple Therapy - for the maintenance treatment of asthma in adults
18 May 2026